US 11,697,654 B2
Kinase inhibitors exhibiting anti-cancer activity and their method of use
Ayyappan Rajasekaran, Glen Mills, PA (US); Jon Swanson, Weldon Spring, MO (US); Peter Kane, Devon (GB); and Julia Foster, Devon (GB)
Assigned to ALLCRON PHARMA INC., Glen Mills, PA (US)
Appl. No. 16/979,602
Filed by ALLCRON PHARMA INC., Glen Mills, PA (US)
PCT Filed Mar. 18, 2019, PCT No. PCT/US2019/022686
§ 371(c)(1), (2) Date Sep. 10, 2020,
PCT Pub. No. WO2019/182944, PCT Pub. Date Sep. 26, 2019.
Claims priority of provisional application 62/647,098, filed on Mar. 23, 2018.
Prior Publication US 2021/0040104 A1, Feb. 11, 2021
Int. Cl. C07D 491/056 (2006.01); A61K 31/4741 (2006.01); A61P 35/00 (2006.01)
CPC C07D 491/056 (2013.01) [A61P 35/00 (2018.01)] 7 Claims
 
1. A compound having formula (I):

OG Complex Work Unit Chemistry
or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein:
R1 is selected from the group consisting of C1-6 alkyl and nitrile;
R2 is selected from the group consisting of

OG Complex Work Unit Chemistry
and R8 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-7 branched alkyl, and C3-7 cycloalkyl.